移植受者医院获得性肺炎有何不同?
移植受者 HAP/VAP 多发生于移植早期,细菌尤其革兰阴性菌特别是铜绿假单胞菌最常见,耐药菌值得关注,机会性病原体虽少见但需纳入鉴别;支气管肺泡灌洗可能提高病原学诊断率并改善预后,抗菌疗程或需长于普通人群,病死率高。
要点
- 移植受者 HAP/VAP 多发生于移植早期,尤其造血干细胞移植中性粒细胞减少期。
- 细菌是首要病因,革兰阴性菌尤其铜绿假单胞菌常见,耐药菌需重点关注。
- 机会性病原体少见但需鉴别,支气管肺泡灌洗可能提高病原学诊断率。
核心结论
- 移植受者 HAP/VAP 常见且与病死率升高相关,该人群管理知识仍有提升空间。
主要发现
- 移植受者 HAP/VAP 多发生于移植早期,尤其造血干细胞移植受者中性粒细胞减少期间。
- 细菌是免疫正常者和移植受者医院获得性肺炎的首要病因,革兰阴性菌尤其铜绿假单胞菌高度流行。
- 多重耐药菌值得特别关注。
- 机会性病原体主要为烟曲霉、耶氏肺孢子菌和巨细胞病毒,但它们是医院获得性肺炎的罕见病因,通常见于未接受抗菌预防的严重免疫抑制患者。
- 进行支气管肺泡灌洗可能提高病原学诊断率,从而改变治疗管理并改善结局。
关键数值与推荐
- 细菌性 HAP/VAP 的最佳抗菌疗程尚未明确,但可能应长于普通人群。
- 移植受者 HAP/VAP 相关病死率高。
临床怎么用
- 移植受者发生 HAP/VAP 时应考虑革兰阴性菌尤其铜绿假单胞菌及多重耐药菌。
- 鉴别诊断需扩展至机会性病原体和非感染性并发症。
- 可考虑支气管肺泡灌洗以提高病原学诊断率。
- 抗菌疗程可能需要长于普通人群。
局限性
- 细菌性 HAP/VAP 的最佳抗菌疗程尚未明确。
- 移植受者 HAP/VAP 管理知识仍有提升空间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are serious complications in transplant patients. The aim of this review is to summarize the evidence regarding nosocomial pneumonia in transplant recipients, including HAP in non-ventilated patients and VAP, and to identify future directions for improvement.A comprehensive literature search in the PubMed/MEDLINE database was performed. Articles written in English and published between 1990 and November 2018 were included. HAP/VAP in transplant patients usually occurs early post-transplant, particularly during neutropenia in haematopoietic stem cell transplant recipients. Bacteria are the leading cause of nosocomial pneumonia for both immunocompetent and transplant recipients, being Gram negative organisms, and especially Pseudomonas aeruginosa, highly prevalent. Multidrug-resistant bacteria are of special concern. Pneumonia in the transplant setting may be caused by opportunistic pathogens, and the differential diagnosis needs to be extended to other non-infectious complications. The most relevant opportunistic pathogens are Aspergillus fumigatus, Pneumocystis jirovecii and cytomegalovirus. Nevertheless, they are an exceptional cause of nosocomial pneumonia, and usually occur in severely immunosuppressed patients not receiving antimicrobial prophylaxis. Performing bronchoalveolar lavage may improve the rate of aetiological diagnosis, leading to a change in therapeutic management and improved outcomes. The optimal length of antibiotic therapy for bacterial HAP/VAP has not been well defined, but it should perhaps be longer than in the general population. Mortality associated with HAP/VAP is high. HAP/VAP in transplant patients is frequent and is associated with increased mortality. There is room for improvement in gaining knowledge about the management of HAP/VAP in this population.
引用
- Gudiol C, Sabé N, Carratalà J, et al. Is hospital-acquired pneumonia different in transplant recipients? Clin Microbiol Infect. 2019. PMID: 30986554. doi:10.1016/j.cmi.2019.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。